About the Authors
Woolcock Institute of Medical Research, Sydney, New South Wales, Australia
The University of Sydney Medical School, Sydney, New South Wales, Australia
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Astrid Lindgren Children's Hospital, Lung and Allergy Unit, Karolinska University Hospital, Stockholm, Sweden
Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
Atkins Center for Weight and Health, University of California, Berkeley, California, United States of America
The University of Sydney Nursing School, Sydney, New South Wales, Australia
The authors have read the journal's policy and have the following conflicts. Guy Marks sits on an advisory board for Novartis who pay an honorarium on his behalf. The unit GBM works in has conducted research funded by AstraZeneca. Peter Cistulli is a chief investigator on sponsored clinical trials in obstructive sleep apnea for ResMed Inc and Exploramed Inc. His department receives equipment support for oral appliance research from SomnoMed Ltd, and he has a pecuniary interest in the company from previous involvement in product development. PAC is also a medical advisor to Exploramed Inc and Zephyr Sleep Technologies. He has received speaker fees/travel support from Res Med Inc Fisher & Paykel Healthcare. Nathaniel Marshall is a lead investigator on 2 clinical trials for adult sleep apnea that have received in-kind support in the form of the investigational drug from Teva Cephalon (Fraser PA USA) and from CSL Biotherapies (Sydney Australia). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: NM BB GM KW CA. Performed the experiments: GM CA. Analyzed the data: BB GM NM. Contributed reagents/materials/analysis tools: GM. Wrote the paper: GM BB NM CA KW PC.